Provectus to hold CC to discuss PV-10 development plan

At 4 pm EDT on June 19, Provectus Biopharmaceuticals (PVCT +9.8%) will hold a conference call to present its plans for the continued development of its cancer drug candidate PV-10. Management will discuss its proposed Phase 3 clinical trial for melanoma and its progress in developing PV-10 for other cancer indications.

Management will also present its plans to monetize PV-10 and PH-10 via licensing and co-development agreements.

This was corrected on 06/12/2014 at 11:05 AM.
From other sites
Comments (4)
  • alphagabby
    , contributor
    Comments (573) | Send Message
    It's about time they got off their lazy, fatcat duffs and do what they are overpaid for. Very disappointed in them, but still support what they are trying to do.
    12 Jun 2014, 10:42 AM Reply Like
  • M Plaut
    , contributor
    Comments (417) | Send Message
    They are moving steadily ahead. The product(s) are doing very well, and having been making only progress. The stock has not been doing as well. As a stockholder I am of course concerned about the stock price, but as a human being I am more concerned about the potential of the product, which is enormous. Not getting BTD is mainly a problem for the stock. It will impact the product very little, if at all.


    Very sloppy of Seeking Alpha to make a text link saying "at 4 PM today" i.e. June 12 when the target clearly says that the CC is June 19!
    12 Jun 2014, 10:58 AM Reply Like
  • JPBill
    , contributor
    Comments (55) | Send Message
    "Very sloppy of Seeking Alpha"


    At least they're consistent M Plaut. Their hatchet pieces on PVCT are filled with misleading information.


    I too am mostly interested in the performance of PV-10. It has done well in trials and will eventually be extraordinarily important to humanity. It works. And it's safe.
    12 Jun 2014, 11:09 AM Reply Like
  • M Plaut
    , contributor
    Comments (417) | Send Message
    I agree that they are consistent and that all "news" about PVCT emphasizes the negative and ignores the positive.


    "Retail investors should be careful here." "Retail investors should stay on the sidelines with this one" " a 59% smackdown in just a few days." "curiously seeming to boast " "Provectus slammed in early trading" "Despite the setback" "The results are impressive at first glance but the veneer comes off "


    Even though the stock price had more than doubled from 0.55 on June 4 to closing at 1.23 yesterday, there was not one message about its gains until today. These are supposed to be news bulletins and not stock advice or opinion, except what they quote from others.
    12 Jun 2014, 02:58 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs